Epoxy Resin Market Worth $9.2 Billion by 2019

  • Epoxy Resin,chemicals,Market
  • PRNewswire

DALLAS, August 28, 2014 /PRNewswire/ -- According to the new research report "Epoxy Resin market by Application (Coatings, Electronics, Construction, Wind Turbine, Composites, and Adhesives) and Geography - Trends & Forecast to 2019" by MarketsandMarkets, the market of epoxy resin is projected to grow from an estimated $5,995.8 million in 2013 to $9,219.1 million by 2019, with a CAGR of 7.4% between 2014 and 2019.

Browse 80 Market Data Tables and 63 Figures spread through 171 Pages and in-depth TOC on "Epoxy Resin market - Trends & Forecast to 2019".

http://www.marketsandmarkets.com/Market-Reports/epoxy-resins-market-762.html

Early buyers will receive 10% customization on reports.

Epoxy resins are thermosetting polymers and known for their high-quality performance in different industrial applications for corrosion protection, thermal stability, mechanical strength, moisture resistivity, adhesion, and so on. The epoxy resins market is very well correlated to its end-user application industry's growth and its widening reach in industrial applications.

Bisphenol A and Epichlorohydrin are major raw materials in the production of epoxy resins, and any change in the demand and supply of these raw materials could have a major impact on the epoxy resin industry. However, due to rising health concerns related to BPA, it is being substituted by other chemical compounds such as bisphenol F in some applications. Although, paints & coatings is the largest application of the resin, the growing demand of the resin in the wind turbine application is expected to become the fastest-growing market.

According to the estimates, the Asia-Pacific region led the market for phthalic anhydride with 57.0% share by volume at the global level in 2013, followed by Europe (20.6%), North America (17.0%), and Rest of the World (5.3%). Around 36.0% of the resin was estimated to be consumed for paints & coatings in 2013. For electrical & electronics and construction applications, the estimated share were 22.5% and 9.2% respectively.


The growth of the epoxy resin market has been studied through in-depth analysis of important factors that drive the market such as growth in the end-user industry, growing wind energy capacity installation with opportunities in green and sustainable epoxies, and growing demand for it in the aerospace industry. However, slow growth in the European and mature markets of the U.S. and Japan are proving to be the important restraining factors for the market.


About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.


This link:http://www.chemcd.com/news/3361.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.